88.34
0.85 (0.97%)
| Previous Close | 87.49 |
| Open | 89.55 |
| Volume | 1,965,671 |
| Avg. Volume (3M) | 1,183,260 |
| Market Cap | 7,671,556,096 |
| Price / Sales | 650.22 |
| Price / Book | 14.54 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2026 |
| Diluted EPS (TTM) | -3.06 |
| Total Debt/Equity (MRQ) | 0.06% |
| Current Ratio (MRQ) | 8.06 |
| Operating Cash Flow (TTM) | -169.86 M |
| Levered Free Cash Flow (TTM) | -68.57 M |
| Return on Assets (TTM) | -25.34% |
| Return on Equity (TTM) | -65.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Spyre Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | 0.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.38 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.71% |
| % Held by Institutions | 106.07% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FAIRMOUNT FUNDS MANAGEMENT LLC | 97.05 | 97.05 | -4,018,101 | -389,956,702 |
| HENDERSON MICHAEL THOMAS | - | 100.32 | -20,000 | -2,006,400 |
| Aggregate Net Quantity | -4,038,101 | |||
| Aggregate Net Value ($) | -391,963,102 | |||
| Aggregate Avg. Buy ($) | 97.05 | |||
| Aggregate Avg. Sell ($) | 98.69 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FAIRMOUNT FUNDS MANAGEMENT LLC | Director | 23 Jun 2026 | Acquired (+) | 666,680 | 97.05 | 64,701,294 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Director | 23 Jun 2026 | Sell (-) | 4,684,781 | 97.05 | 454,657,996 |
| HENDERSON MICHAEL THOMAS | Director | 22 Jun 2026 | Automatic sell (-) | 20,000 | 100.32 | 2,006,400 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |